Eligibility criteria for biologic disease-modifying antirheumatic drugs in axial spondyloarthritis: going beyond BASDAI.
Jose MaronaAlexandre SeprianoSantiago Rodrigues-ManicaFernando Pimentel-SantosAna Filipa MourãoNélia GouveiaJaime Cunha BrancoHelena SantosElsa Vieira-SousaFilipe VinagreJoão Tavares-CostaJoão RoviscoMiguel BernardesNathalie MadeiraRita Cruz-MachadoRaquel RoqueJoana Leite SilvaMary Lucy MarquesRaquel Miriam FerreiraSofia RamiroPublished in: RMD open (2021)
The ASDAS definition of high disease activity is more inclusive than the BASDAI definition in selecting patients with axSpA for bDMARD treatment. The additionally 'captured' patients respond better and have higher likelihood of predictors thereof. These results support using ASDAS≥2.1 as a criterion for treatment decisions.